サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：免疫レパートリーシーケンシングの世界市場- 業界分析、規模、シェア、成長、動向、予測（2031年）- コンポーネント別、用途別、エンドユーザー別、地域別
市場調査レポート
商品コード
1389767

免疫レパートリーシーケンシングの世界市場- 業界分析、規模、シェア、成長、動向、予測（2031年）- コンポーネント別、用途別、エンドユーザー別、地域別

Immune Repertoire Sequencing Market - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America & Middle East & Africa)
出版日: | 発行: Fairfield Market Research | ページ情報: 英文 219 Pages | 納期: 2～5営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
免疫レパートリーシーケンシングの世界市場- 業界分析、規模、シェア、成長、動向、予測（2031年）- コンポーネント別、用途別、エンドユーザー別、地域別
出版日: 2023年11月22日
発行: Fairfield Market Research
ページ情報: 英文 219 Pages
納期: 2～5営業日
  • 全表示
  • 概要
  • 目次
概要

次世代シーケンシング（NGS）技術の最近の進歩は、免疫レパートリーシーケンシングの分野における画期的な発見への道を開きました。B細胞受容体（BCR）とT細胞受容体（TCR）の相補性決定領域をプローブ化するこの最先端技術は、外来病原体に対する身体の防御機構に関する我々の理解に革命をもたらしつつあります。

免疫レパートリーシーケンシングは、侵襲性とサンプル必要量を最小限に抑え、正確で高感度なプラットフォームを提供し、関心領域のダイナミックなビューを提供します。今後、この分野における新たな手法の開発は、特に現在の手法と比較してより包括的なサンプルインサイトを提供できるのであれば、中心的な役割を担うことになるでしょう。免疫レパートリーシーケンシングの将来は、抗原結合細胞を含む、より小さな対象集団に関する高次元の詳細な情報を提供するシングルセルアプローチが主流になると予想されます。

最近の予測によると、世界の免疫レパートリーシーケンシング市場はCAGR 7.3%という驚異的な成長を遂げ、2026年末までに1億7,300万米ドルに達すると予測されています。金額ベースでは、北米が圧倒的な地域市場として台頭し、アジア太平洋でも力強い成長が見込まれています。

北米では、がんや感染症との闘いにおける免疫療法の需要の高まりから、米国が市場をリードすると予想されています。米国国立がん研究所が強調しているように、免疫レパートリーシーケンシング法の開発は、がんに対する進歩において極めて重要な役割を果たすと期待されています。

欧州は免疫レパートリーシーケンシングで2番目に優位な地域市場であり、ヘルスケア支出の増加と政府資金がその原動力となっています。この地域は競合情勢が激しく、多数のメーカーが市場の成長に貢献しています。さらに、ゲノムシーケンスの価格引き下げが免疫レパートリーシーケンシングの需要に拍車をかけています。

アジア太平洋、特に中国と日本は、世界の免疫レパートリーシーケンシング市場で著しい成長を遂げています。同地域における国際的な共同研究や技術の進歩に支えられ、この技術の採用が増加しています。ラテンアメリカは、先進的な製品のイントロダクションと感染症の罹患率の上昇に後押しされて成長を遂げています。

当レポートでは、世界の免疫レパートリーシーケンシング市場について調査し、市場の概要とともに、コンポーネント別、用途別、エンドユーザー別、地域別動向、および市場に参入する企業の競合動向などを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の定義とセグメンテーション
  • 市場力学
  • バリューチェーン分析
  • ポーターのファイブフォース分析
  • COVID-19の影響分析
  • ウクライナとロシアの紛争の影響
  • 経済概要
  • PESTLE分析

第3章 世界の免疫レパートリーシーケンシング市場の見通し、2018年～2031年

  • 世界の免疫レパートリーシーケンシング市場の見通し、コンポーネント別、金額（100万米ドル）、2018年～2031年
  • 世界の免疫レパートリーシーケンシング市場の見通し、用途別、金額（100万米ドル）、2018年～2031年
  • 世界の免疫レパートリーシーケンシング市場の見通し、エンドユーザー別、金額（100万米ドル）、2018年～2031年
  • 世界の免疫レパートリーシーケンシング市場の見通し、地域別、金額（100万米ドル）、2018年～2031年

第4章 北米の免疫レパートリーシーケンシング市場の見通し、2018年～2031年

第5章 欧州の免疫レパートリーシーケンシング市場の見通し、2018年～2031年

第6章 アジア太平洋の免疫レパートリーシーケンシング市場の見通し、2018年～2031年

第7章 ラテンアメリカの免疫レパートリーシーケンシング市場の見通し、2018年～2031年

第8章 中東・アフリカの免疫レパートリーシーケンシング市場の見通し、2018年～2031年

第9章 競合情勢

  • エンドユーザー別と用途別のヒートマップ
  • メーカーと用途別のヒートマップ
  • 企業の市場シェア分析、2023年
  • 競争力ダッシュボード
  • 企業プロファイル
    • Illumina, Inc.
    • Pacific Biosciences of California, Inc
    • Agilent Technologies, Inc
    • Oxford Nanopore Technologies, Ltd
    • QIAGEN N.V.
    • Thermo Fisher Scientific
    • BGI
    • Takara Bio, Inc
    • F. Hoffmann-La Roche Ltd

第10章 付録

目次

Recent advancements in next-generation sequencing (NGS) technology have paved the way for groundbreaking discoveries in the field of immune repertoire sequencing. This cutting-edge technique, which probes the complementarity-determining regions of B-cell receptors (BCRs) and T-cell receptors (TCRs), is revolutionizing our understanding of the body's defense mechanisms against foreign agents.

Immune Repertoire Sequencing Unveils a World of Opportunities

Immune repertoire sequencing offers an accurate and sensitive platform with minimal invasiveness and sample requirement, providing a dynamic view of the region of interest. Looking ahead, the development of new methods in this field is poised to take center stage, particularly if they can offer more comprehensive sample insights compared to current techniques. The future of immune repertoire sequencing is expected to be dominated by single-cell approaches, offering high-dimensional and in-depth information on smaller populations of interest, including antigen-binding cells.

Market Projections and Regional Dominance

According to recent projections, the global immune repertoire sequencing market is set to grow at an impressive CAGR of 7.3% and is anticipated to reach a valuation of US$ 173.0 million by the end of 2026. In terms of value, North America is poised to emerge as the dominant regional market, with strong growth anticipated in Asia Pacific.

In North America, the United States is expected to lead the way due to a growing demand for immunotherapy in the fight against cancer and infectious diseases. Developments in immune repertoire sequencing methods are expected to play a pivotal role in the progress against cancer, as highlighted by the U.S. National Cancer Institute.

Europe is the second dominant regional market for immune repertoire sequencing, driven by increased healthcare expenditure and government funding. This region boasts a highly competitive landscape, with numerous manufacturers contributing to the market's growth. Additionally, price reductions in genome sequencing have spurred the demand for immune repertoire sequencing.

Asia-Pacific, specifically China and Japan, is witnessing significant growth in the global immune repertoire sequencing market. The adoption of this technology is on the rise, supported by international collaborations and technological advancements in the region. Latin America is experiencing growth fueled by advanced product introductions and the rising incidence of infectious diseases.

Conversely, the Middle East & Africa is expected to be the least attractive market due to challenges such as a lack of skilled personnel and limited internet access for data analysis. However, price reductions and international collaborations may spur future growth in this region.

Unlocking the Potential of Immune Repertoire Sequencing

High-throughput sequencing of immunoglobulin and TCR sequences is opening up numerous opportunities for advancing our knowledge of human biology and medicine. Immune repertoire sequencing holds immense promise in biomarker discovery, vaccine development, and transplant selectivity. However, it also comes with its share of challenges, including the need for new sequenced databases, computational algorithms, and advanced software for comprehensive data analysis.

In conclusion, the ever-evolving field of immune repertoire sequencing is poised for continuous growth, driven by scientific breakthroughs in TCR and BCR repertoire research. These developments will serve as the foundation for new clinical applications in personalized medicine, providing deeper insights into the behavior and response of adaptive immunity.

Table of Contents

1. Executive Summary

  • 1.1. Global Immune Repertoire Sequencing Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Immune Repertoire Sequencing Market Outlook, 2018 - 2031

  • 3.1. Global Immune Repertoire Sequencing Market Outlook, by Component, Value (US$ Mn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Assay Kits
        • 3.1.1.1.1. TCR Kits
        • 3.1.1.1.2. BCR Kits
      • 3.1.1.2. Software & Services
        • 3.1.1.2.1. Analytical Software
        • 3.1.1.2.2. Sequencing Services
        • 3.1.1.2.3. Data Analysis Services
  • 3.2. Global Immune Repertoire Sequencing Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Biomarker Discovery
      • 3.2.1.2. Infectious Diseases
      • 3.2.1.3. Vaccine Development and efficacy
      • 3.2.1.4. Cancer Immunotherapy
      • 3.2.1.5. Autoimmune Disease
      • 3.2.1.6. Transplant Rejection and Tolerance
      • 3.2.1.7. Others
  • 3.3. Global Immune Repertoire Sequencing Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Academic Institutes
      • 3.3.1.2. Research Centres
  • 3.4. Global Immune Repertoire Sequencing Market Outlook, by Region, Value (US$ Mn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. North America
      • 3.4.1.2. Europe
      • 3.4.1.3. Asia Pacific
      • 3.4.1.4. Latin America
      • 3.4.1.5. Middle East & Africa

4. North America Immune Repertoire Sequencing Market Outlook, 2018 - 2031

  • 4.1. North America Immune Repertoire Sequencing Market Outlook, by Component, Value (US$ Mn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Assay Kits
        • 4.1.1.1.1. TCR Kits
        • 4.1.1.1.2. BCR Kits
      • 4.1.1.2. Software & Services
        • 4.1.1.2.1. Analytical Software
        • 4.1.1.2.2. Sequencing Services
        • 4.1.1.2.3. Data Analysis Services
  • 4.2. North America Immune Repertoire Sequencing Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Biomarker Discovery
      • 4.2.1.2. Infectious Diseases
      • 4.2.1.3. Vaccine Development and efficacy
      • 4.2.1.4. Cancer Immunotherapy
      • 4.2.1.5. Autoimmune Disease
      • 4.2.1.6. Transplant Rejection and Tolerance
      • 4.2.1.7. Others
  • 4.3. North America Immune Repertoire Sequencing Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Academic Institutes
      • 4.3.1.2. Research Centres
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis
  • 4.4. North America Immune Repertoire Sequencing Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. U.S. Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 4.4.1.2. U.S. Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 4.4.1.3. U.S. Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 4.4.1.4. Canada Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 4.4.1.5. Canada Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 4.4.1.6. Canada Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Immune Repertoire Sequencing Market Outlook, 2018 - 2031

  • 5.1. Europe Immune Repertoire Sequencing Market Outlook, by Component, Value (US$ Mn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Assay Kits
        • 5.1.1.1.1. TCR Kits
        • 5.1.1.1.2. BCR Kits
      • 5.1.1.2. Software & Services
        • 5.1.1.2.1. Analytical Software
        • 5.1.1.2.2. Sequencing Services
        • 5.1.1.2.3. Data Analysis Services
  • 5.2. Europe Immune Repertoire Sequencing Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Biomarker Discovery
      • 5.2.1.2. Infectious Diseases
      • 5.2.1.3. Vaccine Development and efficacy
      • 5.2.1.4. Cancer Immunotherapy
      • 5.2.1.5. Autoimmune Disease
      • 5.2.1.6. Transplant Rejection and Tolerance
      • 5.2.1.7. Others
  • 5.3. Europe Immune Repertoire Sequencing Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Academic Institutes
      • 5.3.1.2. Research Centres
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis
  • 5.4. Europe Immune Repertoire Sequencing Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Germany Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 5.4.1.2. Germany Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 5.4.1.3. Germany Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.4.1.4. U.K. Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 5.4.1.5. U.K. Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 5.4.1.6. U.K. Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.4.1.7. France Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 5.4.1.8. France Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 5.4.1.9. France Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.4.1.10. Italy Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 5.4.1.11. Italy Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 5.4.1.12. Italy Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.4.1.13. Turkey Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 5.4.1.14. Turkey Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 5.4.1.15. Turkey Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.4.1.16. Russia Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 5.4.1.17. Russia Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 5.4.1.18. Russia Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.4.1.19. Rest of Europe Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 5.4.1.20. Rest of Europe Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 5.4.1.21. Rest of Europe Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Immune Repertoire Sequencing Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Immune Repertoire Sequencing Market Outlook, by Component, Value (US$ Mn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Assay Kits
        • 6.1.1.1.1. TCR Kits
        • 6.1.1.1.2. BCR Kits
      • 6.1.1.2. Software & Services
        • 6.1.1.2.1. Analytical Software
        • 6.1.1.2.2. Sequencing Services
        • 6.1.1.2.3. Data Analysis Services
  • 6.2. Asia Pacific Immune Repertoire Sequencing Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Biomarker Discovery
      • 6.2.1.2. Infectious Diseases
      • 6.2.1.3. Vaccine Development and efficacy
      • 6.2.1.4. Cancer Immunotherapy
      • 6.2.1.5. Autoimmune Disease
      • 6.2.1.6. Transplant Rejection and Tolerance
      • 6.2.1.7. Others
  • 6.3. Asia Pacific Immune Repertoire Sequencing Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Academic Institutes
      • 6.3.1.2. Research Centres
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis
  • 6.4. Asia Pacific Immune Repertoire Sequencing Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. China Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 6.4.1.2. China Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 6.4.1.3. China Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.4.1.4. Japan Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 6.4.1.5. Japan Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 6.4.1.6. Japan Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.4.1.7. South Korea Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 6.4.1.8. South Korea Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 6.4.1.9. South Korea Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.4.1.10. India Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 6.4.1.11. India Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 6.4.1.12. India Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.4.1.13. Southeast Asia Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 6.4.1.14. Southeast Asia Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 6.4.1.15. Southeast Asia Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.4.1.16. Rest of Asia Pacific Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 6.4.1.17. Rest of Asia Pacific Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 6.4.1.18. Rest of Asia Pacific Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Immune Repertoire Sequencing Market Outlook, 2018 - 2031

  • 7.1. Latin America Immune Repertoire Sequencing Market Outlook, by Component, Value (US$ Mn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Assay Kits
        • 7.1.1.1.1. TCR Kits
        • 7.1.1.1.2. BCR Kits
      • 7.1.1.2. Software & Services
        • 7.1.1.2.1. Analytical Software
        • 7.1.1.2.2. Sequencing Services
        • 7.1.1.2.3. Data Analysis Services
  • 7.2. Latin America Immune Repertoire Sequencing Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
      • 7.2.1.1. Biomarker Discovery
      • 7.2.1.2. Infectious Diseases
      • 7.2.1.3. Vaccine Development and efficacy
      • 7.2.1.4. Cancer Immunotherapy
      • 7.2.1.5. Autoimmune Disease
      • 7.2.1.6. Transplant Rejection and Tolerance
      • 7.2.1.7. Others
  • 7.3. Latin America Immune Repertoire Sequencing Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Academic Institutes
      • 7.3.1.2. Research Centres
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis
  • 7.4. Latin America Immune Repertoire Sequencing Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Brazil Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 7.4.1.2. Brazil Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 7.4.1.3. Brazil Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 7.4.1.4. Mexico Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 7.4.1.5. Mexico Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 7.4.1.6. Mexico Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 7.4.1.7. Argentina Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 7.4.1.8. Argentina Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 7.4.1.9. Argentina Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 7.4.1.10. Rest of Latin America Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 7.4.1.11. Rest of Latin America Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 7.4.1.12. Rest of Latin America Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Immune Repertoire Sequencing Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Immune Repertoire Sequencing Market Outlook, by Component, Value (US$ Mn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Assay Kits
        • 8.1.1.1.1. TCR Kits
        • 8.1.1.1.2. BCR Kits
      • 8.1.1.2. Software & Services
        • 8.1.1.2.1. Analytical Software
        • 8.1.1.2.2. Sequencing Services
        • 8.1.1.2.3. Data Analysis Services
  • 8.2. Middle East & Africa Immune Repertoire Sequencing Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Biomarker Discovery
      • 8.2.1.2. Infectious Diseases
      • 8.2.1.3. Vaccine Development and efficacy
      • 8.2.1.4. Cancer Immunotherapy
      • 8.2.1.5. Autoimmune Disease
      • 8.2.1.6. Transplant Rejection and Tolerance
      • 8.2.1.7. Others
  • 8.3. Middle East & Africa Immune Repertoire Sequencing Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Academic Institutes
      • 8.3.1.2. Research Centres
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis
  • 8.4. Middle East & Africa Immune Repertoire Sequencing Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. GCC Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 8.4.1.2. GCC Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 8.4.1.3. GCC Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.4.1.4. South Africa Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 8.4.1.5. South Africa Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 8.4.1.6. South Africa Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.4.1.7. Egypt Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 8.4.1.8. Egypt Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 8.4.1.9. Egypt Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.4.1.10. Nigeria Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 8.4.1.11. Nigeria Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 8.4.1.12. Nigeria Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.4.1.13. Rest of Middle East & Africa Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 8.4.1.14. Rest of Middle East & Africa Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 8.4.1.15. Rest of Middle East & Africa Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. By End User vs by Application Heat map
  • 9.2. Manufacturer vs by Application Heatmap
  • 9.3. Company Market Share Analysis, 2023
  • 9.4. Competitive Dashboard
  • 9.5. Company Profiles
    • 9.5.1. Illumina, Inc.
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Product Portfolio
      • 9.5.1.3. Financial Overview
      • 9.5.1.4. Business Strategies and Development
    • 9.5.2. Pacific Biosciences of California, Inc
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Product Portfolio
      • 9.5.2.3. Financial Overview
      • 9.5.2.4. Business Strategies and Development
    • 9.5.3. Agilent Technologies, Inc
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Product Portfolio
      • 9.5.3.3. Financial Overview
      • 9.5.3.4. Business Strategies and Development
    • 9.5.4. Oxford Nanopore Technologies, Ltd
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Product Portfolio
      • 9.5.4.3. Financial Overview
      • 9.5.4.4. Business Strategies and Development
    • 9.5.5. QIAGEN N.V.
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Product Portfolio
      • 9.5.5.3. Financial Overview
      • 9.5.5.4. Business Strategies and Development
    • 9.5.6. Thermo Fisher Scientific
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Product Portfolio
      • 9.5.6.3. Financial Overview
      • 9.5.6.4. Business Strategies and Development
    • 9.5.7. BGI
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Product Portfolio
      • 9.5.7.3. Financial Overview
      • 9.5.7.4. Business Strategies and Development
    • 9.5.8. Takara Bio, Inc
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Product Portfolio
      • 9.5.8.3. Financial Overview
      • 9.5.8.4. Business Strategies and Development
    • 9.5.9. F. Hoffmann-La Roche Ltd
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Product Portfolio
      • 9.5.9.3. Financial Overview
      • 9.5.9.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations